Navigation Links
Vemurafenib New Drug Application Submitted to FDA for Melanoma
Date:5/11/2011

eople worldwide are diagnosed with melanoma each year. It is one of the deadliest cancers, with a five-year survival rate of 15 percent for people with advanced (Stage IV) melanoma, according to the American Cancer Society.

Risk factors for melanoma include a positive family history of melanoma, prior melanoma, multiple clinically atypical moles or dysplastic nevi, inherited genetic mutations, fair skin and sun exposure. However, melanoma can occur in any ethnic group and also in areas of the body without substantial exposure to the sun.

About Vemurafenib (PLX4032)—A Personalized Medicine for Cancer Treatment

Vemurafenib is a novel, oral small molecule for treating melanoma and other cancers harboring the oncogenic BRAF mutation. Plexxikon utilized its structure-guided chemistry platform to discover vemurafenib, and initiated clinical development in 2006. Plexxikon and Roche signed a license and collaboration agreement in 2006 to co-develop vemurafenib. Under a 2005 agreement, a DNA-based companion diagnostic to identify patients whose tumors carry the BRAF mutation is being co-developed by Plexxikon and Roche Molecular Systems in parallel with the therapeutic development of vemurafenib. 

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit '/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Roche Submits Application for Clearance of Chlamydia and Gonorrhoeae Test
2. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
3. ULURU Inc. Announces the Filing of a 510(k) Application for Altrazeal® Collagen
4. Netsmart Technologies Launches Exchange for Customers to Share Applications and Information
5. ePharmaSolutions Launches Major Release of Its Global Safety Letter Distribution and Tracking Application in More Than 90 Countries
6. HealthWarehouse.com Launches Application of Google Commerce Search for Prescription Medications
7. Hospira Submits 510(k) Application to FDA for Symbiq™ Infusion System Modifications
8. Alternative Probiotic Applications Offer $2 Billion+ Market Potential
9. FDA Approves Hyperopia Application for the MEL 80 Excimer Laser from Carl Zeiss Meditec
10. China Medicine Corporation Voluntarily Withdraws Application for Nasdaq Listing
11. EMDT, MD+DI, and Qmed Announce Virtual Event Dedicated to Developments in Materials for Medical Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... About Duchenne muscular dystrophy Duchenne ... affects the male population. It is characterized by ... caused due to mutations in the dystrophin gene, ... dystrophin (a protein essential for maintaining healthy muscle ... muscle function, causes loss of ambulation, harms the ...
(Date:9/2/2015)... -- About Chronic Lymphocytic Leukemia Chronic ... production of lymphocytes. It has been observed that the ... to other parts of the body. This leukemia is ... buildup of the cancerous cells. During the course of ... and lymph nodes. The course of the disease is ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 Research and ... "Pharmaceutical Regulatory Affairs in China (Basel, Switzerland - November ... This seminar will provide a detailed overview of the key ... , Hong Kong , Macau ... cover: - All important aspects of gaining ...
Breaking Medicine Technology:Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
... FRANCISCO, Oct. 14 Medizone International, Inc. ... round of AsepticSure(TM) trials have begun at Innovation Park, ... the first and second round of laboratory testing, this ... protocols necessary in order to obtain maximum bactericidal action ...
... Oct. 14 Cardiva Medical, Inc. announces today that its ... position of Chief Executive Officer at Innovative Energy, Inc., an ... of Cardiva Medical stated, "I would like to thank Glenn ... During his tenure as President, we have transformed Cardiva ...
Cached Medicine Technology:Medizone International Announces Third Round of AsepticSure 2Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc. 2Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc. 3
(Date:9/2/2015)... ... September 03, 2015 , ... The Aspen Clinic (TAC), located ... geared towards kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. , ... a whole mind-body approach to fitness - we are much more than a gym. ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each year, the editors ... public servants, activists, corporate executives, entrepreneurs, health care professionals, and others have had ... led the magazine to tap the National League for Nursing’s outspoken CEO, ...
(Date:9/2/2015)... ... 02, 2015 , ... Healthegy, a leading producer of conferences, ... will deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( http://www.digitalhealthcaresummit.com/ ... , Larry Renfro, CEO of Optum, will deliver the morning address. In his ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... gift from the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham ... the gift comes six months after WCHN recruited nationally known gynecologic oncologist Thomas ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... efficacy endpoint data collection, cloud analytics and workflow solutions today announced the ... enables pharmaceutical researchers to participate in interactive programs in which ERT scientists ...
Breaking Medicine News(10 mins):Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3
... News) -- New research finds that adults who suffered from ... fever -- are nine times more likely to have allergic ... are based on about 1,400 adults who have been followed ... Study. The study participants were assessed in 1968, when they ...
... TUESDAY, April 19 (HealthDay News) -- About 1 in ... -- meaning the virus becomes resistant to multiple drugs ... European study shows. That drug failure rate is ... maintaining viral load suppression in young patients who begin ...
... Amanda Gardner HealthDay Reporter , TUESDAY, April 19 ... for the diagnosis of Alzheimer,s disease could double the number ... guidelines, issued Tuesday by the Alzheimer,s Association and the U.S. ... the last recommendations, which have been in use since 1984. ...
... TUESDAY, April 19 (HealthDay News) -- People who have ... hospital than they did almost two decades ago, but discharges ... a result, Iowa researchers report. Using Medicare data on ... 2008, the researchers found that hospital stays are now averaging ...
... available in French . , Montreal April ... age, yet the reasons for this increasing forgetfulness have not ... older individuals have reduced learning and memory because their minds ... Published in The Quarterly Journal of Experimental Psychology, ...
... Goodwin HealthDay Reporter , TUESDAY, April 19 (HealthDay ... either had or were going to get all of the ... doctor,s advice on immunizations, two new surveys find. Pediatricians ... years of hype about a supposed autism/MMR (measles, mumps, rubella) ...
Cached Medicine News:Health News:Kids' Eczema, Hay Fever Linked to Allergic Asthma Later 2Health News:Children With HIV at Higher Risk of Drug Resistance 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 3Health News:Shorter Hospital Stays, More Readmissions After Hip Replacements 2Health News:Shorter Hospital Stays, More Readmissions After Hip Replacements 3Health News:Spring-cleaning the mind? 2Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 2Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 3
Inquire...
Inquire...
... EDTA K2 or EDTA K3 tubes. ... therefore blocks the coagulation cascade. Erythrocytes, ... anticoagulated blood sample are stable for ... are for the examination of whole ...
... the most powerful, productive ... and rich in features, ... a comprehensive authoring environment ... custom interactive multimedia content ...
Medicine Products: